

RESEARCH PAPER

Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation

Jun-Yan Liu, Hsing-Ju Tsai, Sung Hee Hwang, Paul D Jones, Christophe Morisseau and Bruce D Hammock

Department of Entomology and UCD Cancer Research Center, University of California, Davis, CA, USA

Background and purpose: Early soluble epoxide hydrolase inhibitors (sEHs) such as 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) are effective anti-hypertensive and anti-inflammatory agents in various animal models. However, their poor metabolic stability and limited water solubility make them difficult to use pharmacologically. Here we present the evaluation of four sEHs for improved pharmacokinetic properties and the anti-inflammatory effects of one sEH.

Experimental approach: The pharmacokinetic profiles of inhibitors were determined following p.o. (oral) administration and serial bleeding in mice. Subsequently the pharmacokinetics of *trans*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (*t*-AUCB), the most promising inhibitor, was further studied following s.c. (subcutaneous), i.v. (intravenous) injections and administration in drinking water. Finally, the anti-inflammatory effect of *t*-AUCB was evaluated by using a lipopolysaccharide (LPS)-treated murine model.

Key results: Better pharmacokinetic parameters (higher C_{max} , longer $t_{1/2}$ and greater AUC) were obtained from the tested inhibitors, compared with AUDA. Oral bioavailability of *t*-AUCB ($0.1 \text{ mg}\cdot\text{kg}^{-1}$) was $68 \pm 22\%$ ($n = 4$), and giving *t*-AUCB in drinking water is recommended as a feasible, effective and easy route of administration for chronic studies. Finally, *t*-AUCB (p.o.) reversed the decrease in plasma ratio of lipid epoxides to corresponding diols (a biomarker of soluble epoxide hydrolase inhibition) in lipopolysaccharide-treated mice. The *in vivo* potency of $1 \text{ mg}\cdot\text{kg}^{-1}$ of *t*-AUCB (p.o.) was better in this inflammatory model than that of $10 \text{ mg}\cdot\text{kg}^{-1}$ of AUDA-butyl ester (p.o.) at 6 h after treatment.

Conclusions and implications: *t*-AUCB is a potent sEH with improved pharmacokinetic properties. This compound will be a useful tool for pharmacological research and a promising starting point for drug development.

British Journal of Pharmacology (2009) **156**, 284–296; doi:10.1111/j.1476-5381.2008.00009.x; published online 19 January 2009

Keywords: bioavailability; efficacy; LC-MS/MS; LPS; murine; oxylipin mediators; pharmacokinetics; sEH inhibitor

Abbreviations: ADU, 1-adamantanyl-3-decylurea; AEPU, 1-adamantanyl-3-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl]urea; AIC, Akaike information criterion; *c*-AUCB, *cis*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid; *t*-AUCB, *trans*-AUCB; APAU, 1-(1-acetypiperidin-4-yl)-3-adamantanylurea; AUDA, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid; AUDA-BE, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester; BPAU, 1-(5-butoxypentyl)-3-adamantylurea; CMNPC, cyano(2-methoxynaphthalen-6-yl)methyl(3-phenyloxiran-2-yl)methyl carbonate; EET, epoxyeicosatrienoic acid; DHET, dihydroxyeicosatrienoic acid; DHOME, dihydroxy octadecamonoenoic acid; EpOME, epoxyoctadecamonoenoic acid; HETE, hydroxyeicosatetraenoic acid; NF- κ B, nuclear factor kappa B; LPS, lipopolysaccharide; PG, prostaglandin; PK, pharmacokinetic; sEH, soluble epoxide hydrolase; sEHI, sEH inhibitor; TOIC₅₀, time of blood concentration over IC₅₀; TPAU, 1-trifluoromethoxyphenyl-3-(1-acetypiperidin-4-yl) urea

Introduction

Epoxyeicosatrienoic acids (EETs) are a group of four physiologically and/or pharmacologically active regioisomers

derived from metabolism of arachidonic acid (AA) by cytochrome P450 (Spector *et al.*, 2004). These mediators are vasodilators in various animal models (Carroll *et al.*, 1987a,b; Imig *et al.*, 1995; Pomposiello *et al.*, 2003; Seubert *et al.*, 2007) and play an important role in regulation of blood pressure as well as control and prevention of heart disease (Sarkis and Roman, 2004; Doggrell, 2005; Imig, 2005; Elbekai and El-Kadi, 2006; Seubert *et al.*, 2007). EETs also have potent anti-inflammatory properties mediated through the nuclear factor

Correspondence: Bruce D Hammock, Department of Entomology and UCD Cancer Research Center, University of California, One Shields Avenue, Davis, CA 95616, USA. E-mail: bdhammock@ucdavis.edu

Received 16 June 2008; revised 12 August 2008; accepted 20 August 2008




Figure 1 The structures of the inhibitors tested. Chemical names and synonyms of the four compounds are provided in the abbreviations. APAU, 1-(1-acetypiperidin-4-yl)-3-adamantanylurea; *c*-AUCB, *cis*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid; *t*-AUCB, *trans*-AUCB; TPAU, 1-(1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea.

kappa B (NF- κ B) and I κ B kinase system (Node *et al.*, 1999; Campbell, 2000; Xu *et al.*, 2006). Metabolism of EETs by soluble epoxide hydrolase (sEH) results in their conversion to the more polar and less active dihydroxyeicosatrienoic acids (DHETs) (Newman *et al.*, 2005; Morisseau *et al.*, 2006b). Thus, stabilizing or increasing the concentration of EETs through inhibition of sEH with sEH inhibitors (sEHIs) is a novel and effective approach to prevention and/or treatment of hypertension (Imig *et al.*, 2002; 2005; Zhao *et al.*, 2002; Imig, 2006), inflammation (Olearczyk *et al.*, 2005; Schmelzer *et al.*, 2005; Smith *et al.*, 2005) and other cardiovascular diseases (Imig, 2005; Davis *et al.*, 2006; Jin *et al.*, 2006; Ng *et al.*, 2006; Schmelzer *et al.*, 2006; Seubert *et al.*, 2006; Xu *et al.*, 2006; Inceoglu *et al.*, 2007). Although treatment with sEHIs reduces blood pressure in several animal models of hypertension, high doses of sEHIs have not been observed to reduce blood pressure in normotensive animals. Interestingly, the same compounds can raise blood pressure in acute hypotension, such as that following treatment with lipopolysaccharide (LPS) (Schmelzer *et al.*, 2005). The anti-hypertensive and anti-hypotensive effects occur by different mechanisms of EET action (Node *et al.*, 1999; Fleming and Busse, 2006). However, stabilization of EETs by sEHI are the same for both treating hypertension and in this study, hypotension.

N,N'-Disubstituted ureas and related compounds lead to the attenuation of the hydrolysis of lipid epoxides in many *in vitro* and *in vivo* models at low concentrations (Morisseau *et al.*, 1999; Dorrance *et al.*, 2005; Imig *et al.*, 2005; Schmelzer *et al.*, 2005; Davis *et al.*, 2006; Inceoglu *et al.*, 2006; Olearczyk *et al.*, 2006b; Xu *et al.*, 2006). Early urea-based inhibitors having two hydrophobic substituents on both nitrogen atoms, such as *N,N'*-dicyclohexylurea (DCU) or *N*-adamantyl-*N'*-cyclohexylurea (ACU), are potent sEHIs, but their poor water solubility has limited their use *in vivo* (Morisseau *et al.*, 1999; 2002). Thus, compounds with a polar functional group(s) on one side of the urea, such as 1-adamantanyl-3-[5-[2-(2-ethoxyethoxy)ethoxy]pentyl] urea (AEPU), 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) and its *n*-butyl ester (AUDA-BE), were found to have improved water solubility while maintaining their potency (Morisseau *et al.*, 2002; 2006a; Kim *et al.*, 2004; 2005). These

three compounds were found to be potent inhibitors of the sEH in several animal models (Dorrance *et al.*, 2005; Schmelzer *et al.*, 2005; 2006; Smith *et al.*, 2005; Olearczyk *et al.*, 2006a).

AUDA and its esters represented improvements in development of sEHIs but retained poor water solubility. They require careful formulation for oral administration and are rapidly metabolized by beta-oxidation. The improved water solubility and high oral availability of AEPU made it a useful compound. In several systems, its biological activity *in vivo* was greater than that predicted by its potency and blood levels. However, its very rapid cytochrome P450-mediated hydroxylation limits its utility in small animals with a rapid heartbeat. We hypothesized that a long alkyl chain on these inhibitors was metabolically susceptible. Accordingly, the sEHIs with conformationally restricted *N,N'*-Disubstituted ureas harbouring polar groups were synthesized; they are potent sEHIs having better water solubility and greater *in vivo* stability (Jones *et al.*, 2006).

In addition to the *in vitro* potency, the assessment of pharmacokinetic properties and *in vivo* efficacy are deemed critical for the evaluation of a drug candidate. In this paper, we compare the pharmacokinetic profile of four conformationally restricted sEHIs with high *in vitro* potency on both murine and human sEHs. In addition to the use of a conformationally restricted group rather than a long chain alkyl group on the 3 position of the urea, we also evaluated a trifluoromethoxyphenyl group to replace the sometimes metabolically labile adamantane in the 1 position of the urea. *Trans*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (*t*-AUCB) and its *cis*-isomer (*c*-AUCB) (Hwang *et al.*, 2007), as well as two piperidine-containing inhibitors 1-(1-acetylpiperidin-4-yl)-3-adamantanylurea (APAU) and 1-(1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea (TPAU) (Jones *et al.*, 2006; Hwang *et al.*, 2007) were evaluated in mice following administration by oral gavage (Figure 1). Subsequently, the pharmacokinetics of *t*-AUCB, the most promising inhibitor, was further determined following s.c. (subcutaneous) or i.v. (intravenous) injections and being provided in the drinking water. Finally, the *in vivo* efficacy of *t*-AUCB was evaluated by using a murine model of LPS-challenged inflammation.

Methods

Animals

All animal procedures and experiments were performed according to protocols approved by the Animal Use and Care Committee of University of California-Davis. Mice (male CFW strain, 7 weeks old, 24–30 g; and male C57BL/6 strain, 8 weeks old, 22–25 g) were purchased from Charles River Laboratories.

Determination of *in vitro* IC₅₀

The *in vitro* IC₅₀ values of the four inhibitors of human, rat and mouse sEHs were determined by using previously reported methods using cyano(2-methoxynaphthalen-6-yl)methyl(3-phenyloxiran-2-yl)methyl carbonate (CMNPC) as substrate. Human, mouse and rat sEHs were incubated with inhibitors for 5 min in 25 mmol·L⁻¹ Bis-Tris/HCl buffer (200 μL; pH 7.0) at 30°C before addition of the fluorescent substrate (CMNPC; 5 μmol·L⁻¹). In each case, the appropriate affinity purified recombinant enzyme was used (Morisseau *et al.*, 1999; Jones *et al.*, 2005; Morisseau and Hammock, 2007). The rates of formation of the fluorescent product were linear for the duration of the assay. Results are averages of three separate measurements, each based on a range of concentrations both above and below the IC₅₀.

Determination of water solubility

Each inhibitor (3 mg) was suspended in 2 mL of nanopure water in a 4 mL glass vial by strong mixing on a Vortex mixer for 5 min and then followed by sonication for 1 h in a 40°C water bath. The suspension was then shaken at 250 r.p.m. with an L.E.D. orbit shaker (Lab-Line Instruments, Inc. Melrose Park, IL) at room temperature for 2 days. The suspension was allowed to settle for 1 day at room temperature, and then it was centrifuged at 10 956×*g* for 15 min. An aliquot of supernatant was diluted with methanol (1000–5000-fold) for LC-MS/MS analysis. Each sample was analysed in triplicate.

Pharmacokinetic protocols

Male CFW mice (7 week old, 24–30 g) were used for pharmacokinetic studies. Inhibitors for oral administration were dissolved in triolein or triolein containing 1% ethanol to give a clear solution. For s.c. injection, *t*-AUCB was dissolved in 100 mmol·L⁻¹ sodium phosphate buffer (pH = 7.4) containing 10% alpha-tocopherol polyethylene glycol succinate and 20% 2-hydroxypropyl-β-cyclodextrin. For i.v. injection, the *t*-AUCB (dose: 0.1 mg·kg⁻¹) was dissolved in 100 mmol·L⁻¹ sodium phosphate buffer (pH = 7.4). Blood (10 μL) was collected from the tail vein by using a pipette tip rinsed with 7.5% EDTA(K₃) at 0, 30, 60, 90, 120, 240, 360, 480 and 1440 min after dosing with the inhibitor. The number of animals in each group was presented in Tables 2, 4 and 5. For the drinking water study, *t*-AUCB was delivered the drinking water at 4 mg·L⁻¹ containing 0.4% [volume in volume (v/v)] ethanol. Each mouse was housed in a separate cage in order to

monitor the daily water and drug intake. Blood (10 μL) was collected daily, and the water intake was recorded. Each blood sample was immediately transferred to a tube containing 50 μL of water and mixed followed by addition of 200 μL of ethyl acetate. After mixing strongly on a Vortex for 1 min, all samples were stored at –80°C until analysis. In a separate previous study, no difference was observed if the ethyl acetate was added before freezing or after thawing.

Preparation of blood samples for the pharmacokinetic study

The extraction of sEHs from blood was performed by a slight modification of a previous method (Watanabe *et al.*, 2006). Specifically, surrogate solution [10 μL, 250 ng of 1-(5-butoxypentyl)-3-adamantylurea (BPAU) in 1 mL of methanol] was added to each thawed blood sample. Samples were mixed on a Vortex mixer for 1 min followed by centrifugation at 10 956×*g* for 5 min. The supernatant was transferred to a new tube, and the residue was extracted with a second 200 μL of ethyl acetate. The supernatants were then combined, and the mixture was evaporated to dryness by using a centrifugal vacuum concentrator. Finally, 50 μL of internal standard solution [100 ng·mL⁻¹ of 1-adamantanyl-3-decylurea (ADU) in methanol] was used to reconstitute the residue for LC-MS/MS analysis. The internal standard ADU was used to analyse the surrogate's recovery and monitor the instrument response, which varied slightly varying from run to run. Here the surrogate standard BPAU was a chemically similar compound to the four tested sEHs, but not present in the blood samples. The recovery of BPAU was used to monitor the gross sample processing errors. The recovery is determined by comparing the measured concentration with the amount added to the sample. The use of both a surrogate that monitors sample work-up from extraction and an internal standard that monitors actual analytical conditions provides tight control of the process and facilitates rapid trouble-shooting. Only slight differences were observed in the accuracy of interest analytes between the treatments with addition of the surrogate (BPAU) prior to and after addition of ethyl acetate by calibration with interest analytes spike.

Analysis of sEH inhibitors in blood samples

The blood concentration of sEHs was determined by using a UPLC-MS/MS method, which was validated to assure acceptable accuracy and precision (accuracy more than 95% with RSD less than 10%). Specifically, chromatographic separation was performed on an ACQUITY ultra performance liquid chromatography (UPLC) instrument equipped with a 2.1 × 50 mm ACQUITY UPLC BEH C₁₈ 1.7 μm column (Waters, Milford, MA) held at 25°C. The solvent system consisted of water/acetonitrile/formic acid (899/100/1 v/v, solvent A) and acetonitrile/water/formic acid (899/100/1 v/v; solvent B). The gradient was begun at 30% solvent B and was gradually increased in a linear manner to 100% solvent B in 5 min. This was maintained for 3 min, then returned to 30% solvent B in 2 min. The flow rate was 0.4 mL·min⁻¹. The injection volume was 5 μL, and the samples were kept at 4°C in the auto sampler. Analytes were detected by positive mode electrospray ionization tandem quadrupole mass

spectrometry in multiple reaction-monitoring mode (MRM) on a Quattro Premier Mass Spectrometer (Waters, Milford, MA). The flow rate of nitrogen gas was fixed for the cone gas flow of 50 L·h⁻¹ and the desolvation gas flow of 650 L·h⁻¹. Electrospray ionization was performed with a capillary voltage set at 1.00 kV and an extractor fixed at 3.0 V. The source temperature was set at 120°C and the desolvation temperature at 300°C respectively. Collision gas (argon) was set at 3.0 × 10⁻³ Torr. Cone voltage and collision voltage were optimized by acquisition of precursor and production ions respectively. The precursor and dominant daughter ions were used to set up the transition monitored in the MRM mode (See supporting information, Table S1).

Pharmacokinetic analysis

The pharmacokinetic parameters of individual mice were first calculated by fitting the time dependent curve of blood concentration data to a non-compartmental analysis with the WinNonlin software (Pharsight, Mountain View, CA). Further, the pharmacokinetic parameters of individual mice were calculated with 1- or 2-compartment analyses with WinNolin software. A first order absorption model was used for s.c. and p.o. (oral) administration, and an i.v.-bolus model was used for i.v. injection respectively. The compartmental model used was selected by comparison of Akaike information criterion (AIC) and/or the correlation coefficient between the observed values and predicted values from different compartmental models. The model associated with the smallest AIC is regarded as giving the best fit. Parameters estimated include the elimination rate constant (λ_z), time of maximum concentration (T_{max}), maximum concentration (C_{max}), half life ($t_{1/2}$), half life of distribution phase ($t_{1/2\alpha}$), half life of elimination phase ($t_{1/2\beta}$), area under the concentration-time curve extrapolated to infinity (AUC_i), area under the concentration-time curve to terminal time (AUC_t), clearance (Cl), apparent volume distribution (V_d), volume distribution at steady state (V_{dss}), the mean residence time (MRT) and the time of blood concentration over IC₅₀ (TOIC₅₀). AUC_t was calculated by the linear/log trapezoidal rule.

Evaluation of the *in vivo* efficacy of t-AUCB

C57BL/6 mice were used in all treatments. Four animals were assigned at random to each group. t-AUCB or AUDA-butyl ester (AUDA-BE) were given by oral gavage immediately after i.p. (intraperitoneal) injection of LPS (10 mg·kg⁻¹) in saline. Mice receiving oral gavage of triolein after i.p. injection of LPS or saline served as positive and negative controls respectively. Mice were killed 6 h after treatment. Blood was collected by cardiac puncture by using an EDTA-rinsed syringe. In order to stabilize the oxylipins, 10 µL combinations of antioxidants (EDTA (0.2 mg·L⁻¹), butylated hydroxytoluene (0.2 mg·L⁻¹), triphenylphosphine (2 mg·L⁻¹) and the non-selective cyclooxygenase inhibitor indomethacin (2 mg·L⁻¹) in MeOH/H₂O (1/1, v/v) were added to each collection tube. Each sample was centrifuged immediately at 685 × g for 10 min, and the plasma was separated. All samples were stored at -80°C until analysis. Blood pressure was determined 4 h after treatment with non-invasive tail cuff methods by using a

Visitech BP-2000 (Visitech Systems, Apex, NC) (Schmelzer *et al.*, 2005).

Plasma sample preparation for the analysis of oxylipin profiling

Aliquots of plasma (250 µL) were spiked with a set of odd chain length analogues and deuterated isomers of several target analytes including hydroxyeicosatetraenoic acids (HETEs), prostaglandins, thromboxanes, epoxides [epoxyoctadecamonoenoic acids (EpOMEs) and EETs] and diols [dihydroxy octadecamonoenoic acids (DHOMEs) and DHETs] contained in 10 µL of methanol, and then were extracted by solid phase extraction by using Oasis HLB cartridges (Waters, Milford, MA). The HLB columns (1 cc, 60 mg) were washed with 2 mL methanol and pre-conditioned with 2 mL water/methanol/acetic acid (95/5/0.1, v/v). Samples were then mixed with 250 µL of the pre-conditioning solution and loaded onto the column. The loaded column was then washed with 2 mL of the pre-conditioning solution and then dried for 5 min *in vacuo*. Target analytes were then eluted with 2 mL of ethyl acetate. The collected eluents were evaporated to dryness by using a centrifugal vacuum concentrator and re-dissolved in 50 µL of methanol containing internal standards (Table S2). The spiked samples were vigorously mixed with a Vortex mixer for 1 min, centrifuged at 10 956 × g for 5 min and then transferred to analytical vials containing 150 µL inserts for analysis.

Analysis of oxylipin profiling

The oxylipin profiling was performed by using a modification of previously published methods (Newman *et al.*, 2002; Luria *et al.*, 2007). The separation of plasma oxylipins was conducted in a Shimadzu LC-10AD_{VP} instrument (Shimadzu Corp., Kyoto, Japan) equipped with a 2.1 mm × 150 mm Pursuit XRs-C18 5 µm column (Varian Inc, Palo Alto, CA) held at 40°C. A gradient of water containing 0.1% acetic acid (v/v, solvent A) and acetonitrile/methanol/acetic acid (800/150/1, v/v; solvent B) was used to elute the column with the flow rate of 0.4 mL·min⁻¹ (Table S3). The injection volume was 20 µL, and the samples were kept at 4°C in the auto sampler. Analytes were detected by negative mode electrospray ionization tandem quadrupole mass spectrometry in MRM mode on a Quattro Ultima Mass Spectrometer (Micromass, Manchester, UK). Nitrogen gas flow rates were fixed with the cone gas flow of 50 L·h⁻¹ and the desolvation gas flow of 750 L·h⁻¹. Electrospray ionization was performed with a capillary voltage set at 3.20 kV and an extractor fixed at 3.0 V. The source temperature was set at 125°C and the desolvation temperature at 400°C respectively. Collision gas argon was set at 3.0 × 10⁻³ Torr. Cone voltage and collision voltage were optimized by acquisition of precursor and production ions respectively. The precursor and dominant daughter ions were used to set up the transition monitored in the MRM mode (Table S2).

Statistical analysis

All results were expressed as mean ± s.d. unless other noted. The experimental results of *in vivo* efficacy study were

analysed by ANOVA by using the software SPSS 10.0 (SPSS Inc., Chicago, IL) with $P < 0.05$ as the significance level.

Materials

Methanol, acetonitrile, ethyl acetate and ethanol were purchased from Fisher Scientific (Pittsburgh, PA). Formic acid, acetic acid and LPS (*Escherichia coli* serotype 0111:B4) were purchased from Sigma-Aldrich (St. Louis, NJ). EDTA(K₃) was purchased from Tyco Health Group LP (Mansfield, MA). Water

(>18.0 MΩ) was purified by a NANO pure system (Barnstead, Newton, MA). All the sEHs used in this study were synthesized in our laboratory, and their structures and purity were supported by chromatographic and spectral analysis (TLC, MS, NMR and LC-MS). The abbreviations and/or nomenclature of chemicals conform with the BJP's guide to Receptors and Channels (Alexander *et al.*, 2008).

Results

In vitro inhibitory activity and water solubility of four sEH inhibitors

As shown in Table 1, *c*- and *t*-AUCBs were of similar *in vitro* potency to AUDA while APAU and TPAU were somewhat less potent. Compared with AUDA and AUDA-BE, all four compounds had significantly better water solubility, suggesting that these new sEHs would be easier to formulate and would have higher oral bioavailability.

Pharmacokinetic profile of the four inhibitors following oral administration

The use of both an internal standard (DCU) and a surrogate standard (BPAU) in the analytical procedure for the sEHs in blood resulted in data with high accuracy (more than 95%) and precision (RSD ≤ 10%). The recovery of the surrogate standard BPAU for each extracted sample was more than 85%, indicating high extraction efficiency and minimal loss in transfer. Figure 2 illustrated the blood concentration following oral administration throughout the complete time course (1440 min) for all four inhibitors. As expected, large variations (RSD up to 180%) were observed at most time

Table 1 *In vitro* activity and water solubility of the sEH inhibitors

Inhibitors	IC ₅₀ (nmol·L ⁻¹)			Water solubility (mg·L ⁻¹)
	Human sEH	Mouse sEH	Rat sEH	
<i>t</i> -AUCB	1.3 ± 0.1	8 ± 1	8 ± 1	160 ± 20
<i>c</i> -AUCB	0.9 ± 0.1	4 ± 0.5	7 ± 1	220 ± 2
APAU	7.0 ± 0.5	9 ± 1	6 ± 0.5	310 ± 60
TPAU	12 ± 1	97 ± 8	79 ± 6	73 ± 9
AUDA	3.0 ± 0.5	10 ± 1	11 ± 2	29 ± 5
AUDA-BE	0.8 ± 0.2	4 ± 1	5 ± 1	5 ^a

Data represent mean ± s.d. ($n = 3$).

Human, mouse and rat sEHs were incubated with inhibitors for 5 min in 25 mmol·L⁻¹ Bis-Tris/HCl buffer (200 μL; pH 7.0) at 30°C before addition of fluorescent substrate [cyano(2-methoxynaphthalen-6-yl)methyl(3-phenyloxiran-2-yl)methyl carbonate; 5 μmol·L⁻¹]. Results in the table are averages of three separate measurements each based on multiple concentrations both above and below the IC₅₀.

APAU, 1-(1-acetylpiperidin-4-yl)-3-adamantanylurea; AUDA, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid; AUDA-BE, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester; *c*-AUCB, *cis*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid; sEH, soluble epoxide hydrolase; *t*-AUCB, *trans*-AUCB; TPAU, 1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea.

^aValue is from Kim *et al.* (2007).

Table 2 Pharmacokinetic parameters of sEH inhibitors after oral gavage with a non-compartmental analysis

Inhibitors (animal number)	Dose (mg·kg ⁻¹)	R ^{2a}	T _{max} ^a (min)	C _{max} ^a (nmol·L ⁻¹)	MRT ^b (min)	TOIC ₅₀ ^a (h)
<i>t</i> -AUCB ^b ($n = 4$)	1.0 (2.43 ^c)	0.5223 ± 0.1043	30 ± 0	150 ± 23	1200 ± 250	>24
	0.5 (1.21 ^c)	0.6440 ± 0.0750	30 ± 0	100 ± 13	900 ± 180	>24
	0.1 (0.24 ^c)	0.4125 ± 0.2045	40 ± 15	30 ± 5	900 ± 190	2 ± 0
<i>c</i> -AUCB ^b ($n = 4$)	1.0 (2.43 ^c)	0.3073 ± 0.3273	40 ± 15	55 ± 11	2000 ± 800	>24
	0.5 (1.21 ^c)	0.3898 ± 0.1594	30 ± 0	30 ± 3	1800 ± 400	>24
	0.1 (0.24 ^c)	0.6367 ± 0.2821	40 ± 15	3.6 ± 0.3	240 ± 30	0
APAU ^b ($n = 4$)	1.0 (3.12 ^c)	0.3596 ± 0.1056	30 ± 0	53 ± 28	1300 ± 500	8 ± 0
	0.5 (1.56 ^c)	0.5095 ± 0.2606	60 ± 14	30 ± 6	900 ± 200	5.5 ± 2.4
	0.1 (0.31 ^c)	0.3548 ± 0.1024	200 ± 90	25 ± 15	1400 ± 700	0.6 ± 0.6
TPAU ^b ($n = 4$)	1.0 (2.90 ^c)	0.4410 ± 0.4074	280 ± 150	273 ± 8	1900 ± 1000	21 ± 1
	0.5 (1.45 ^c)	0.5516 ± 0.3719	230 ± 200	80 ± 8	1000 ± 1300	0
	0.1 (0.29 ^c)	0.4992 ± 0.2874	260 ± 220	30 ± 1	380 ± 10	0
AUDA ^c ($n = 3$)	5.0 (12.7 ^c)	0.7980	42 ± 12	66 ± 31	550 ± 160	1.5
AUDA-BE ^{c,d} ($n = 3$)	5.0 (11.15 ^c)	0.8143	60	100	480	2.5

APAU, 1-(1-acetylpiperidin-4-yl)-3-adamantanylurea; AUDA, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid; AUDA-BE, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester; *c*-AUCB, *cis*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid; sEH, soluble epoxide hydrolase; *t*-AUCB, *trans*-AUCB; TPAU, 1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea.

^aR² is the square of the correlation coefficient between predicted and observed value; T_{max}, time of maximum concentration; C_{max}, the maximum blood concentration; MRT, mean residence time; and TOIC₅₀, time of blood concentration over IC₅₀. Additional pharmacokinetic parameters with non-compartmental model are presented in Table S4.

^bData represent the mean ± s.d. of four mice; 10 ul of blood was collected from the tail vein of mice at 0, 30, 60, 90, 120, 240, 360, 480 and 1440 min after dosing with the inhibitors.

^cData represent the mean ± s.d. or mean of three mice from previous work (Watanabe *et al.*, 2006; Kim *et al.*, 2007).

^dAUDA is the predominant metabolite with little or none of the parent ester detected in the blood, thus the parameters were calculated on the basis of the blood concentration of AUDA.

^eThe dose expressed as μmol·kg⁻¹.




Figure 2 Blood concentration–time course of four inhibitors after administration by oral gavage to mice. (A) *t*-AUCB, (B) *c*-AUCB, (C) APAU and (D) TPAU. Each point represents the mean \pm s.d. of four mice plotted in a log/linear scale. Blood was collected from the tail vein of mice at 0, 30, 60, 90, 120, 240, 360, 480 and 1440 min after dosing with the inhibitors respectively. The dotted line represents the IC_{50} of the respective inhibitor with the murine soluble epoxide hydrolase. APAU, 1-(1-acetypiperidin-4-yl)-3-adamantanylurea; *c*-AUCB, *cis*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid; *t*-AUCB, *trans*-AUCB; TPAU, 1-trifluoromethoxyphenyl-3-(1-acetyl piperidin-4-yl) urea.

points between individuals. Interestingly, *t*-AUCB (Figure 2A) had far higher blood concentrations than the corresponding *cis*-isomer (Figure 2B). In the case of the compounds containing a piperidine group, the replacement of an adamantyl group (APAU, Figure 2C) with a trifluoromethoxyphenyl group (TPAU, Figure 2D) resulted in higher blood concentrations. These results suggested that the pharmacokinetic properties can be easily affected by a minor structural change and that there is some metabolic lability to the adamantane.

Table 2 summarizes the pharmacokinetic parameters on the basis of non-compartmental analysis. R^2 was used to evaluate the correlation between the observed and predicted values. Overall, even at a dose of $1 \text{ mg}\cdot\text{kg}^{-1}$, blood levels and pharmacokinetic parameters obtained from the four tested inhibitors were better than those obtained from AUDA and AUDA-BE at $5 \text{ mg}\cdot\text{kg}^{-1}$ doses. T_{\max} and C_{\max} roughly reflect the average rate of inhibitor absorption. Except for TPAU, the C_{\max} s of the other three inhibitors were above their *in vitro* IC_{50} s for the murine sEH at all three investigated doses. For

these three compounds, their T_{\max} s occurred at approximately 30 min, suggesting these compounds are rapidly absorbed. However, TPAU had a C_{\max} higher than its IC_{50} for the murine sEH only at the highest tested dose, and its T_{\max} was almost 4 h for all three doses, suggesting that this derivative is more slowly absorbed. The relatively poor *in vitro* inhibition of murine sEH and the large inter-individual variations in blood levels made TPAU less desirable for use in murine disease models. However, it should be noted that TPAU had desirable properties in other species including primates.

A 2-compartment model is the best fit model for *t*-AUCB and *c*-AUCB, while a 1-compartment model is the best one for APAU and TPAU on basis of comparison of AICs and the correlation coefficients between observed and predicted values. Table 3 summarizes AUCs and $t_{1/2}$ s of the inhibitors from 1- or 2-compartment model analyses. AUC is used to evaluate the systemic exposure of inhibitors. The large AUCs of the four novel inhibitors were most likely due to improved absorption and/or slow elimination. Replacing the metabolically susceptible long alkyl chain in AUDA with a conforma-

Table 3 Key pharmacokinetic parameters of *t*-AUCB and *c*-AUCB following p.o. or s.c. administration with 1- or 2-compartment analysis

Inhibitors	Dose (mg·kg ⁻¹)	Compartmental(s)	AIC ^a	Corr ^a	AUC _t ^a (μmol·L ⁻¹ ·min)	<i>t</i> _{1/2e} ^a (min)	<i>t</i> _{1/2β} ^a (min)	<i>t</i> _{1/2} ^a (min)
<i>t</i> -AUCB ^d (p.o.)	1.0 (2.43 ^g)	2	60.7 ± 10.0	0.9894 ± 0.0086	155 ± 50	15 ± 10	>1440 ^b	—
	0.5 (1.21 ^g)	2	56.1 ± 9.0	0.9913 ± 0.0050	60 ± 35	30 ± 10	1100 ± 500 ^c	—
	0.1 (0.24 ^g)	2	60.1 ± 10.0	0.8660 ± 0.1064	15 ± 5	20 ± 8	>1440 ^b	—
<i>c</i> -AUCB ^d (p.o.)	1.0 (2.43 ^g)	2	32.2 ± 12.9	0.9972 ± 0.0014	55 ± 3	30 ± 20	>1440 ^b	—
	0.5 (1.21 ^g)	2	57.9 ± 18.1	0.9648 ± 0.0020	30 ± 10	40 ± 30	>1440 ^b	—
	0.1 (0.24 ^g)	2	22.6 ± 12.6	0.9076 ± 0.0355	2 ± 1	45 ± 15	180 ± 40	—
APAU ^d (p.o.)	1.0 (3.12 ^g)	1	62.0 ± 1.1	0.7522 ± 0.2110	12 ± 7	—	—	310 ± 250
	0.5 (1.56 ^g)	1	56.0 ± 6.8	0.8305 ± 0.0974	11 ± 5	—	—	180 ± 80
	0.1 (0.31 ^g)	1	48.9 ± 8.8	0.6732 ± 0.2152	9 ± 1	—	—	560 ± 490
TPAU ^d (p.o.)	1.0 (2.90 ^g)	1	78.9 ± 14.2	0.9533 ± 0.0371	390 ± 180	—	—	>1440 ^b
	0.5 (1.45 ^g)	1	72.3 ± 7.1	0.7593 ± 0.1462	48 ± 40	—	—	800 ^f
	0.1 (0.29 ^g)	1	48.3 ± 8.2	0.9214 ± 0.0481	11 ± 5	—	—	240
<i>t</i> -AUCB ^d (s.c.)	10.0 (24.25)	1	123.3 ± 7.7	0.9753 ± 0.0156	320 ± 90	—	—	75 ± 55
	3.0 (7.28 ^g)	1	91.7 ± 11.6	0.9616 ± 0.0373	100 ± 40	—	—	85 ± 35
	1.0 (2.43 ^g)	1	80.7 ± 4.5	0.9761 ± 0.0003	25 ± 10	—	—	60 ± 40
AUDA ^e (p.o.)	5.0 (12.7 ^g)	2	52.2	0.9916	24	13	575	—
AUDA-BE ^g (p.o.)	5.0 (11.15 ^g)	2	58.0	0.9956	16	30	260	—

APAU, 1-(1-acetylpiperidin-4-yl)-3-adamantanyllurea; AUDA, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid; AUDA-BE, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester; *c*-AUCB, *cis*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid; *t*-AUCB, *trans*-AUCB; TPAU, 1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea.

^aAIC, Akaike information criterion; AUC_t, area under the concentration–time curve to terminal time; Corr, correlation coefficient between observed values and predicted values; *t*_{1/2e}, half life of α phase (note that this phase is not a distribution phase, but a combined result of distribution and absorption); *t*_{1/2β}, half life of elimination phase; the absorption rate constants are presented in Table S7.

^bThe calculated value is more than the maximum sampling time, 1440 min.

^cThe sampling time approaches the calculated *t*_{1/2e}, so these calculated data are approximate results.

^dData represent average ± s.d. of three or four mice. Oral treatments were as same as that in Table 2, and s.c. injection was as same as that in Table 4.

^eData represent the mean of three mice. The parameters are from Kim *et al.* (2007) and Watanabe *et al.* (2006).

^fAUDA is the predominant metabolite with little or none of the parent ester detected in the blood, thus the parameters were calculated on the basis of the blood concentration of AUDA.

^gThe dose expressed as μmol·kg⁻¹.

^hThis value is an estimate as it should be more than 1440 min. We would need a longer sampling time to calculate a firm value.

ⁱThis is an approximate result, as it is based on the last two time points only.

Table 4 Pharmacokinetic parameters of *t*-AUCB (*Trans*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid) after s.c. injection with non-compartmental analysis

Dose (mg·kg ⁻¹) (animal number)	R ^{2a}	T _{max} ^a (min)	C _{max} ^a (nmol·L ⁻¹)	MRT ^a (min)	TOIC ₅₀ ^a (h)
10 (24.25 ^b , n = 3)	0.6791 ± 0.0528	40 ± 14	3600 ± 1100	70 ± 20	8
3 (7.28 ^b , n = 3)	0.8590 ± 0.0908	60 ± 0	2700 ± 2700	79 ± 9	8
1 (2.43 ^b , n = 3)	0.8928 ± 0.0338	40 ± 14	245 ± 70	110 ± 20	4

Data represent the mean ± s.d. of three mice; 10 µL of blood was collected from the tail vein of mice at 0, 30, 60, 90, 120, 240, 360, 480 and 1440 min after dosing with the inhibitor.

^aR² is the square of the correlation coefficient between predicted and observed values; T_{max}, time of maximum concentration; C_{max}, maximum concentration; MRT, mean residence time; λ_z, elimination rate constant; V_d, apparent volume distribution; TOIC₅₀, the time of blood concentration over IC₅₀. Additional pharmacokinetic parameters are presented in Table S6.

^bThe dose expressed as µmol·kg⁻¹.

tionally restricted group as in APAU as well as in *c*- and *t*-AUCB resulted in longer terminal t_{1/2}s. The same conclusion was supported by the average time of inhibitors residing in the body (MRT).

The two phases of the blood kinetics of *t*-AUCB were more defined than those of *c*-AUCB. However, it should be noted that the α phase is not a simple distribution phase but a combined result of the distribution and absorption. Among the three other tested inhibitors, the highest C_{max} and the biggest AUCs were obtained from *t*-AUCB among the doses tested. Even though the similar blood t_{1/2α}s and t_{1/2β}s were obtained to *c*-AUCB, the lowest inter-individual variations were obtained for *t*-AUCB. Lacking quantitative *in vivo* efficacy comparing these inhibitors, the *in vitro* IC₅₀s were used as cursory predictors of the biological effects. The blood concentrations of *t*-AUCB and *c*-AUCB were higher than their IC₅₀s at doses of 0.5 and 1 mg·kg⁻¹ even after 24 h treatment. Based on these results, along with its suitable t_{1/2} of 10–14 h and its relative species-independent potency on the sEH target (human, rats and mice), *t*-AUCB appeared to be the best of the derivatives tested as an sEHI, with good blood kinetics, for further investigation in murine inflammation and possibly other disease models.

Pharmacokinetic profile of *t*-AUCB following s.c. injection

Figure 3 illustrates the time course of blood concentration following s.c. injection at three different doses of 1, 3 and 10 mg·kg⁻¹ respectively. The pharmacokinetic parameters from non- and 1-compartment model analyses are summarized in Tables 3 and 4 respectively. The blood C_{max} of *t*-AUCB is achieved in 40–60 min after its administration, as it was for the oral route (Table 4). Subcutaneous injection resulted in a higher C_{max} but a shorter t_{1/2} than those from oral gavage. For the dose of 1 mg·kg⁻¹, s.c. injection resulted in a blood concentration above the IC₅₀ for 4 h and below IC₅₀ after 6 h, whereas oral gavage resulted in a blood concentration above IC₅₀ through the whole investigated 24 h. This observation suggests that administration by oral gavage releases the drug more slowly than s.c. injection, and thus is better at maintaining an effective drug concentration. For both oral gavage and s.c. injection, we observed a linear increase in the AUC as a function of the dose given (Figure 3 insert).

Pharmacokinetic profile of *t*-AUCB following i.v. injection

Figure 4 illustrates the pharmacokinetic profile of *t*-AUCB following i.v. injection. The pharmacokinetic parameters




Figure 3 Blood concentration–time course of *t*-AUCB (*Trans*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid) after s.c. administration to mice. Each point represents the mean ± s.d. of three mice. Insert: dependence of the AUC_i (area under the concentration–time curve extrapolated to infinity) on dose given to the animal for p.o. (data from Figure 2, R² = 0.9825) and s.c. administrations (R² = 0.9989). Blood was collected from the mice through the tail vein at 0, 30, 60, 90, 120, 240, 360, 480 and 1440 min after dosing with the inhibitors respectively.

from non-compartmental analysis are included in Table S4. However, it is clearly observed that *t*-AUCB has two phases of excretion including distribution (α) and elimination (β) phases. Table 5 summarizes the pharmacokinetic parameters on the basis of 2-compartment model analysis. Specifically, the distribution phase had a sharp slope with t_{1/2α} of 70 min, while the elimination phase had a flat slope with t_{1/2β} of around 10 h. V_{dss} was used to roughly evaluate the extensive tissue distribution of *t*-AUCB. V_{dss} was 17 L·kg⁻¹ indicating a high peripheral tissue distribution of *t*-AUCB *in vivo*. This may result from the lipophilicity of *t*-AUCB. The blood clearance of *t*-AUCB was 0.7 L·kg⁻¹·h⁻¹, corresponding to the long elimination half life.

Bioavailability of *t*-AUCB

Bioavailability is calculated from the time course of blood concentrations (estimated as AUC) following non-intravenous administration relative to that following i.v. injection with a dose that yields appropriate blood concentrations. The AUC_is of *t*-AUCB following p.o., s.c. and i.v.




Figure 4 Blood concentration–time course of *Trans*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (*t*-AUCB) with i.v. administration to mice. Insert: blood concentration–time course of *t*-AUCB with i.v. administration to mice plotted in a log/linear scale. Each point represents the mean \pm s.d. of three animals. Blood was collected from the tail vein of mice at 0, 30, 60, 90, 120, 240, 360, 480 and 1440 min after dosing with the inhibitor respectively.

Table 5 Pharmacokinetic parameters of *t*-AUCB (*Trans*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid) following i.v. injection by 2-compartment analysis

Pharmacokinetic parameters	Units	Values ^a
AIC ^b	–	64.5 \pm 4.6
Corr ^b	–	0.9650 \pm 0.01400
$t_{1/2\alpha}$ ^b	min	70 \pm 30
$t_{1/2\beta}$ ^b	min	600 \pm 120
Cl ^{**b}	L·h ⁻¹ ·kg ⁻¹	0.7 \pm 0.1
AUC _t ^b	μ mol·L ⁻¹ ·min	22 \pm 4
V _{dss} ^b	L·kg ⁻¹	17 \pm 7

^aData represent average \pm s.d. of three mice. The dose treated was 0.1 mg·kg⁻¹ (0.24 μ mol·kg⁻¹); 10 μ L of blood was collected from the tail vein of mice at 0, 30, 60, 90, 120, 240, 360, 480 and 1440 min after dosing with the inhibitors.

^bAIC, Akaike information criterion; AUC_t, area under the concentration–time curve to terminal time; Corr, correlation coefficient between observed values and predicted values; $t_{1/2\alpha}$, half life of distribution phase; $t_{1/2\beta}$, half life of elimination phase; Cl, clearance; V_{dss}, volume distribution at steady state; The pharmacokinetic parameters with a non-compartmental model are presented in Table S4.

injection are summarized in Tables 3 and 5. Accordingly, its oral bioavailabilities were 70 \pm 23%, 55 \pm 32% and 68 \pm 22% for the doses of 1.0, 0.5 and 0.1 mg·kg⁻¹ respectively. The s.c. bioavailabilities were 14 \pm 4%, 15 \pm 6% and 11 \pm 4% for the doses of 10, 3 and 1 mg·kg⁻¹ respectively.

Pharmacokinetic profile of *t*-AUCB administered in drinking water

A simple method of giving the sEHIs over several days, was required to evaluate the biological function of these inhibitors in a chronic model. This should be best achieved by giving the sEHI in drinking water which would result in a fairly steady blood level over the time of treatment. In order to test this proposal, *t*-AUCB at a dose of 4 mg·L⁻¹ was provided in drinking water, which is roughly equivalent to an




Figure 5 *t*-AUCB administration increases the systolic blood pressure of LPS-treated mice. This is a hypotensive model. Successful therapy is shown by a reversal to the normotensive state. Each bar represents the mean \pm s.d. ($n = 4$). The blood pressure reported here was determined 4 h post treatment. In the group receiving LPS and AUDA-BE, the blood pressure of two mice was under the limit of detection, so we recorded the data as the limit of detection (40 mm Hg). *Significantly different from the control group receiving vehicle only ($P < 0.05$); #significantly different from the group receiving LPS only ($P < 0.05$); \$significantly different from the group receiving LPS and *t*-AUCB (1 mg·kg⁻¹). Significant differences were determined by ANOVA followed by Tukey's test. AUDA-BE, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester; LPS, lipopolysaccharide; *t*-AUCB, *Trans*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid.

oral dose of 1 mg·kg⁻¹ per day per mouse, assuming that a 30 g mouse drinks 7.5 mL of water a day. As expected, a relatively stable blood level of 70 nmol·L⁻¹ *t*-AUCB was attained after 1 day administration and maintained for the following days. The *t*-AUCB was totally washed out in 3 days with an apparent half life of 18 h, which corresponded to the elimination half life obtained from p.o. administration. This suggests that this simple method of administration is feasible and is probably suitable for many chronic studies in a murine model. However, it should be noted that 'diseased' mice may drink much more or less water than the normal controls in some disease models.

Regulation of hypotension in LPS-treated mice by oral gavage of *t*-AUCB

Hypotension is a critical feature of models of septic shock challenged by LPS. As illustrated in Figure 5, the systolic blood pressure dramatically decreased below our reliable detection limit (40 mm Hg) 4 h after giving LPS (10 mg·kg⁻¹). As expected, doses of 0.5 and 1 mg·kg⁻¹ *t*-AUCB dramatically reversed the systolic blood pressure up to ~60% and 90% of the normal level respectively. However, 1 mg·kg⁻¹ of *t*-AUCB, without LPS treatment, had no significant effect on the blood pressure. These observations suggest that *t*-AUCB ameliorates the LPS-induced hypotension in a dose-dependent manner. In comparison with *t*-AUCB, oral administration of 10 mg·kg⁻¹ of the early potent sEHI AUDA-BE to four mice given LPS resulted in systolic blood pressure of ~45% of the normal level with no significant difference from the LPS control. These results suggest that *t*-AUCB is at least 10-fold more potent

than AUDA-BE 4 h after treatment. AUDA-BE is metabolized to the free acid AUDA by esterase soon after administration, and a previous study showed that oral administration of 5 mg·kg⁻¹ of AUDA-BE resulted in a similar blood concentration profile of AUDA to that of oral administration of 5 mg·kg⁻¹ of AUDA (Table 2) (Kim *et al.*, 2007). Together, these data indicate that *t*-AUCB is more potent than AUDA in this murine sepsis model.

In vivo efficacy of *t*-AUCB inhibiting the sEH in mice treated with LPS

P450 monooxygenases catalyse the formation of EET and EpOMes from AA and linoleic acid respectively. The mono epoxy EETs and EpOMes are further metabolized by sEH to their 1,2-diols (DHETs and DHOMes). Therefore, sEHI has the ability to inhibit the production of diols (DHETs and DHOMes) and/or increase the stability of epoxides (EETs and EpOMes), resulting in an increase in the epoxide to diol ratios. These alterations are critical to evaluation of the *in vivo* efficacy of sEHIs. Following treatment with LPS, there is a dramatic increase in the pro-inflammatory mediators including TXB₂, PGE₂ and 5-HETE, accompanied by a large increase in NO from inducible NO synthase (iNOS), indicating that these mice are in an inflammatory state (Schmelzer *et al.*, 2005). This is consistent with the dramatic fall in systolic blood pressure.

The total epoxides, total diols and the ratio of epoxides to diols from our present experiments are shown in Table 6. LPS dramatically stimulated the production of diols including DHOMes and DHETs, and thus significantly decreased the ratio of epoxides to corresponding diols. As expected, both doses of *t*-AUCB significantly reduced the production of diols in the DHOME and DHET families, and significantly increased the ratios of epoxides to diols in a dose-related manner. Overall, these results showed that the inhibition of sEH by *t*-AUCB was certainly associated with the regulation of hypotension in mice treated with LPS. Furthermore, LPS, with or without *t*-AUCB, changed the production of diols and the ratio of epoxides to diols. This indicates that the ratio of epoxides to diols could be a valuable biomarker of LPS-induced inflammation and the potency of sEHI to address inflammation. In the control animals receiving only 1 mg·kg⁻¹ of *t*-AUCB, there was just a slight increase in the sum of EETs, as well as in the EET/DHET ratio. As in previous studies, the effects of sEHI in normal animals on blood epoxides and diols are much smaller than that in animals with inflammation (Schmelzer *et al.*, 2006).

AUDA-BE (10 mg·kg⁻¹) significantly inhibited the production of diols and increased the ratio of epoxides to diols in LPS-treated mice (Table 6). This potency is similar to that of 1 mg·kg⁻¹ of *t*-AUCB. These results also suggest that *t*-AUCB is at least 10-fold more potent *in vivo* than AUDA-BE, 6 h after treatment.

Discussion

Inspection of the structures of the four inhibitors shown in Figure 1 reveals that APAU has the same 'left side' of an

Table 6 Total oxylipin epoxides and diols in murine plasma

Groups	LPS (mg·kg ⁻¹)	<i>t</i> -AUCB (mg·kg ⁻¹)	ΣEpOME ^a (nmol·L ⁻¹)	ΣDHOME ^b (nmol·L ⁻¹)	ΣEpOME/ΣDHOME	ΣEET ^c (nmol·L ⁻¹)	ΣDHET ^d (nmol·L ⁻¹)	ΣEET/ΣDHET
<i>t</i> -AUCB control	0	1.0	43 ± 14	32 ± 2	1.4 ± 0.1	7.4 ± 1.7	6.2 ± 0.3	1.2 ± 0.3
Control	0	0	50 ± 30	34 ± 13	1.4 ± 0.4	5.8 ± 2.1	5.9 ± 1.0	1.0 ± 0.4
LPS control	10	0	26 ± 6 ^g	190 ± 60 ^g	0.15 ± 0.04 ^g	4.0 ± 1.6 ^g	14.5 ± 3.0 ^g	0.3 ± 0.1 ^g
<i>t</i> -AUCB (dose 1)	10	0.5	16 ± 3 ^{g,h}	63 ± 7 ^{g,h}	0.26 ± 0.08 ^g	3.3 ± 1.0 ^g	5.7 ± 1.2 ^h	0.6 ± 0.1 ^{g,h}
<i>t</i> -AUCB (dose 2)	10	1.0	40 ± 20	80 ± 30 ^{f,g,h}	0.5 ± 0.2 ^{f,g,h}	4.6 ± 1.5	5.8 ± 1.4 ^{g,h}	0.8 ± 0.1 ^{g,h}
AUDA-BE	10	10	29 ± 7	60 ± 12 ^h	0.5 ± 0.1 ^h	3.0 ± 1.0	4.7 ± 0.8 ^h	0.7 ± 0.3 ^h

Each value represents the mean ± s.d. of four mice. Mice were killed 6 h post treatment. For the concentration of individual epoxide or diol regioisomers see Table S5.

AUDA-BE, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester; DHOME, dihydroxy octadecamonoenoic acid; EET, epoxyeicosatrienoic acid; EpOME, epoxyoctadecamonoenoic acid; HETE, hydroxyeicosatetraenoic acid; LPS, lipopolysaccharide; sEH, soluble epoxide hydrolase; *t*-AUCB, *trans*-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid.

^aConcentration of combined regioisomers of linoleate (18:2) epoxides.

^bConcentration of combined regioisomers of linoleate diols.

^cEpoxide to diol ratios in the linoleate (18:2) and arachidonate series (20:4) are apparent biomarkers of the inhibition of sEH.

^dConcentration of combined regioisomers of arachidonate (20:4) epoxides. The 5,6-isomer is not included as it forms a lactone during sample preparation and analysis.

^eConcentration of combined regioisomers of arachidonate diols.

^fSignificantly different from the control group (second row) ($P < 0.05$); ^gsignificantly different from the *t*-AUCB control (first row) ($P < 0.05$); ^hsignificantly different from the LPS control group (third row) ($P < 0.05$). All significant differences were determined by ANOVA followed by Tukey's test.

adamantanyl urea as *t*-AUCB and *c*-AUCB and has the same 'right side' of an acetyl piperidine as TPAU. Both *t*-AUCB and *c*-AUCB have shorter T_{max} and higher AUC than APAU, which indicates that the right side of AUCB (cyclohexyloxy-benzoic acid) may be more favourable than acetyl piperidine for higher blood levels in this model. Interestingly, higher C_{max} and overall blood concentrations were obtained for *t*-AUCB than its *cis*-isomer, although the difference was small. In comparison with APAU, the replacement of the 'left side' adamantyl by a 4-trifluoromethoxy-phenyl in TPAU results in far higher C_{max} and AUC, but a longer T_{max} , suggesting a slower but more efficient absorption, and/or slower metabolism and distribution of the compound. However, TPAU is far less potent than APAU with respect to *in vitro* inhibition of sEH in rodents. Because the potency of the two piperidines is similar for human sEH, TPAU could be more effective and long lasting in humans and other primates than APAU or *t*- and *c*-AUCB. These observations could be valuable for the design of new potent sEHIs, bearing in mind that blood levels for pharmaceutical agents often do not correlate with efficacy. For example, the early sEHI, AUDA, has been shown to penetrate the blood-brain barrier and to show benefits in a stroke model (Zhang *et al.*, 2007). Another early sEHI, AEPU, attenuated inflammation induced cardiac hypertrophy without detectable amounts in the blood, indicating that its biological effects were due to the rapid tissue distribution of sEHI or active metabolite (Xu *et al.*, 2006). Although adamantane has a near perfect fit in the sEH catalytic site based on X-ray crystallography (Jones *et al.*, 2006), with some sEHI, it provides metabolic lability. The higher AUC of TPAU suggests that replacement of adamantane should be considered if a larger AUC is desired. In both the cyclohexylbenzyl ether series and the acetyl piperidine series, blood half-lives should be easily adjusted by replacing adamantane. For the inhibitors *t*-AUCB, *c*-AUCB and TPAU, their AUCs with oral administration are approximately proportional to the doses used. However, the fact that the AUCs of the inhibitor APAU are not proportional to the low doses used, indicates there is a process that is non-linear during the drug absorption and/or metabolism. For the dose of 1 mg·kg⁻¹ of *t*-AUCB, the difference in bioavailability following administration by p.o. and s.c. injection demonstrate that formulation and treatment methods affect drug release, absorption and metabolism.

The intensity of the pharmacological effect of sEH inhibition is a function of the drug potency and the effective amount of drug at the target site. The IC_{50} value, the blood concentration, AUC and the time for which the blood concentration of compounds is above the IC_{50} (TOIC₅₀ in Table 2), suggest characteristics for the effectiveness of a compound. Among the four inhibitors investigated, both *t*-AUCB and *c*-AUCB were better than APAU and TPAU because of their longer TOIC₅₀s and more potent IC_{50} s. Regarding the geometric isomerism of AUCB, the *trans*-isomer gives both a higher C_{max} and larger AUC than the *cis*-isomer; while their $t_{1/2}$ s are not significantly different at the highest concentration. Data with *t*-AUCB also show less variability. Thus *t*-AUCB was selected for further study in the murine model.

The pharmacokinetic properties of *t*-AUCB were also studied by using i.v. and oral administration (via drinking

water). For the i.v. injection, a much shorter $t_{1/2\beta}$ was obtained than that obtained by oral gavage suggesting that even though oral gavage gave a C_{max} after 40 min, there is probably a slow absorption from the gut and/or slow appearance in the bloodstream from tissue depots. This is also supported by the fact that the blood concentration of *t*-AUCB at 8 h was more (or not less) than those at 6 h following oral gavage (Figure 2). Following oral administration in the drinking water, a fairly stable concentration of *t*-AUCB was maintained for several days. While these results are preliminary to establishing a proper dose regimen, they are helpful for the selection of proper administration methods for various murine models of disease.

With the oral dose of 1 mg·kg⁻¹, all four inhibitors showed higher AUCs and longer TOIC₅₀s than those exhibited by AUDA and AUDA-BE with oral doses of 5 mg·kg⁻¹ (Tables 2 and 3). It should be noted that AUDA is the only metabolite of AUDA-BE (through esterase action) and is the only metabolite detected with significant potency on the sEH (Kim *et al.*, 2007). A previous study demonstrated that oral administration of 5 mg·kg⁻¹ of AUDA-BE resulted in a C_{max} of 100 nmol·L⁻¹ for AUDA at the T_{max} of 1 h post treatment in mice, and the blood concentration of AUDA exceeded the IC_{50} for less than 4 h (Kim *et al.*, 2007). Compared with oral gavage of 5 mg·kg⁻¹ of AUDA or AUDA-BE, oral administration of 0.5 mg·kg⁻¹ of *t*-AUCB showed better pharmacokinetic properties such as T_{max} , C_{max} , $t_{1/2}$, AUC and TOIC₅₀. These results suggest that *t*-AUCB should be a better candidate to use for studies *in vivo* than AUDA or AUDA-BE. In addition, its increased water solubility makes *t*-AUCB easier to formulate (Table 1).

The substrate of P450 monooxygenase for the production of EETs is arachidonic acid, which is stored in the cell membrane phospholipids and is released in response to stimuli such as LPS. In a large number of experiments of differing design, we routinely find that the concentrations of epoxides and diols and epoxide to diol ratios are changed slightly or not at all in control animals receiving sEHI only, but the changes are often dramatic in animals with inflammation. LPS dramatically increases the release of arachidonic acid and leads to induction of COX-2 and 5-LOX (Schmelzer *et al.*, 2005; 2006). The resulting inflammatory eicosanoids have a major impact on pain and inflammatory symptoms. There also is a massive increase in iNOS resulting in morbid hypotension. The sEHIs increase EETs and other epoxy lipids that repress the induction of COX-2 and 5-LOX. Although EETs dilate some vessels, in this case their repression of the induction of iNOS dominates the biological outcome, and there is a net rise in blood pressure towards normotensive levels. In general, increased EETs and thus sEHIs quell the propagation of severe inflammation and shift the eicosanoid profile towards active resolution of inflammation. In addition to a significant shift in production of epoxides and diols, *t*-AUCB significantly inhibited the production of TXB₂ and 5-HETE (Table S5) in our LPS model. Our hypothesis is that small changes in EETs can result in large changes in TXB₂ and 5-HETE by transcriptional regulation of their biosynthetic enzymes. Through the combination of the preservation of systolic blood pressure and the shift in production of epoxides and diols, *t*-AUCB was anti-inflammatory in LPS-treated mice. A previous study showed that AUDA-BE significantly

preserved the systolic blood pressure and reversed the decrease in the ratio of epoxides to diols, 24 h after LPS challenge (Schmelzer *et al.*, 2005). The fact that AUDA-BE did not significantly restore the systolic blood pressure in our model, although it affected the epoxides to diols ratio suggest that 4 h may be not the most appropriate time to assess the effects of AUDA-BE on blood pressure. The current study shows that *t*-AUCB was more potent than AUDA-BE not only in reversing the LPS-induced hypotension 4 h after LPS challenge, but also in reversing the decrease in the epoxides to diols ratio, 6 h after LPS treatment. Lipid epoxide concentrations and their ratios to their respective diols are suggested biomarkers for the action of sEHI and alterations in sEHI message. Furthermore, *t*-AUCB afforded higher C_{max} , faster T_{max} , longer $t_{1/2}$, and larger AUC than AUDA-BE and AUDA. It is therefore reasonable to suggest that *t*-AUCB is more potent as a sEHI *in vivo* than AUDA or AUDA-BE, in this murine model.

In conclusion, our study showed that *t*-AUCB is a better sEHI than AUDA and AUDA-BE in terms of *in vivo* potency and pharmacokinetic properties. This is reflected in the improvement in efficacy of *t*-AUCB over AUDA-BE in reversing both LPS-challenged hypotension and the decreased ratio of epoxides to diols. We predict that *t*-AUCB will be a better pharmacological tool than AUDA for testing the role of sEH in a variety of inflammatory and possibly other disease models in mice.

Acknowledgements

The authors thank Dr Christine Hegedus for language review and Pharsight Corporation for providing us the free software of WinNonLin. This work was supported in part by NIEHS grant ES02710, NIEHS Superfund P42 ES04699 and NIH R01 HL85727.

Conflict of interest

HJT, SHH, PDJ, CM and BDH are authors of composition of matter and use patents in this area. BDH is the founder of Arête Therapeutics. This company is moving sEHI through clinical trials for treating hypertension, inflammation and other disorders.

References

Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. *Br J Pharmacol* **153**: S1–S209.

Campbell WB (2000). New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. *Trends Pharmacol Sci* **21**: 125–127.

Carroll MA, Schwartzman M, Capdevila J, Falck JR, McGiff JC (1987a). Vasoactivity of arachidonic acid epoxides. *Eur J Pharmacol* **138**: 281–283.

Carroll MA, Schwartzman ML, Capdevila J, Falck JR, Carrara MC, McGiff JC (1987b). Vascular activity of 5,6 epoxyeicosatrienoic acid. *Clin Res* **35**: A266–A266.

Davis BB, Morisseau C, Newman JW, Pedersen TL, Hammock BD, Weiss RH (2006). Attenuation of vascular smooth muscle cell pro-

liferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. *J Pharmacol Exp Ther* **316**: 815–821.

Doggrell SA (2005). Cytochrome P-450: a new target in the heart and coronary circulation. *Drugs Future* **30**: 261–269.

Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD (2005). An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. *J Cardiovasc Pharmacol* **46**: 842–848.

Elbekai RH, El-Kadi AOS (2006). Cytochrome P450 enzymes: central players in cardiovascular health and disease. *Pharmacol Ther* **112**: 564–587.

Fleming I, Busse R (2006). Endothelium-derived epoxyeicosatrienoic acids and vascular function. *Hypertension* **47**: 629–633.

Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock B (2007). Orally bioavailable potent soluble Epoxide Hydrolase (sEH) inhibitors. *J Med Chem* **50**: 3825–3840.

Imig JD (2005). Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. *Am J Physiol Renal Physiol* **289**: F496–F503.

Imig JD (2006). Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. *Cardiovasc Drug Rev* **24**: 169–188.

Imig JD, Falck JR, Navar LG (1995). 11,12-Epoxyeicosatrienoic acid (11,12-Eet) is a potent vasodilator of the renal microvasculature. *J Am Soc Nephrol* **6**: 679–679.

Imig JD, Zhao XY, Capdevila JH, Morisseau C, Hammock BD (2002). Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. *Hypertension* **39**: 690–694.

Imig JD, Zhao XY, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW *et al.* (2005). An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. *Hypertension* **46**: 975–981.

Inceoglu B, Schmelzer K, Jinks S, Waite T, Hammock B (2006). Soluble epoxide hydrolase inhibitors and/or epoxyeicosatrienoic acids attenuate hyperalgesia and allodynia in a rat model. *FASEB J* **20**: A687–A687.

Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD (2007). Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). *Prostaglandins Other Lipid Mediat* **82**: 42–49.

Jin LM, Foss CE, Zhao XY, Mills TM, Wang MH, McCluskey LP *et al.* (2006). Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. *FASEB J* **20**: 539–541.

Jones PD, Wolf NM, Morisseau C, Whetstone P, Hock B, Hammock BD (2005). Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. *Anal Biochem* **343**: 66–75.

Jones PD, Tsai HJ, Do ZN, Morisseau C, Hammock BD (2006). Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. *Bioorg Med Chem Lett* **16**: 5212–5216.

Kim IH, Morisseau C, Watanabe T, Hammock BD (2004). Design, synthesis, and biological activity of 1,3-Disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. *J Med Chem* **47**: 2110–2122.

Kim IH, Heitzler FR, Morisseau C, Nishi K, Tsai HJ, Hammock BD (2005). Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. *J Med Chem* **48**: 3621–3629.

Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T *et al.* (2007). Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. *Bioorganic. Med Chem* **15**: 312–323.

Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang HP *et al.* (2007). Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. *J Biol Chem* **282**: 2891–2898.

Morisseau C, Hammock BD (2007). Measurement of soluble epoxide hydrolase (sEH) activity. *Curr Protoc Toxicol* **33**: 1–18.

- Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR *et al.* (1999). Potent urea and carbamate inhibitors of soluble epoxide hydrolases. *Proc Natl Acad Sci USA* **96**: 8849–8854.
- Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD (2002). Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. *Biochem Pharmacol* **63**: 1599–1608.
- Morisseau C, Newman JW, Tsai HJ, Baecker PA, Hammock BD (2006a). Peptidyl-urea based inhibitors of soluble epoxide hydrolases. *Bioorg Med Chem Lett* **16**: 5439–5444.
- Morisseau C, Schmelzer K, Pedersen T, Eiserich J, Pinkerton K, Imig J *et al.* (2006b). Physiological roles of soluble epoxide hydrolase and therapeutic prospects of its inhibition. *FASEB J* **20**: A669–A669.
- Newman JW, Watanabe T, Hammock BD (2002). The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. *J Lipid Res* **43**: 1563–1578.
- Newman JW, Morisseau C, Hammock BD (2005). Epoxide hydrolases: their roles and interactions with lipid metabolism. *Prog Lipid Res* **44**: 1–51.
- Ng VY, Morisseau C, Falck JR, Hammock BD, Kroetz DL (2006). Inhibition of smooth muscle proliferation by urea-based alkanolic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. *Arterioscler Thromb Vasc Biol* **26**: 2462–2468.
- Node K, Huo YQ, Ruan XL, Yang BC, Spiecker M, Ley K *et al.* (1999). Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. *Science* **285**: 1276–1279.
- Olearczyk JJ, Kim IH, Hammock BD, Imig JD (2005). Inhibition of the soluble epoxide hydrolase decreases the expression of pro-inflammatory genes in hypertensive Goto-Kakizaki rats. *Hypertension* **46**: 856–856.
- Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD (2006a). Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. *J Pharmacol Exp Ther* **318**: 1307–1314.
- Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD (2006b). Urea-based soluble epoxide hydrolase inhibitors dilate mesenteric resistance vessels. *FASEB J* **20**: A669–A669.
- Pomposiello SI, Quilley J, Carroll MA, Falck JR, McGiff JC (2003). 5,6-epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR. *Hypertension* **42**: 548–554.
- Sarkis A, Roman RJ (2004). Role of cytochrome P450 metabolites of arachidonic acid in hypertension. *Curr Drug Metab* **5**: 245–256.
- Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD (2005). Soluble epoxide hydrolase is a therapeutic target for acute inflammation. *Proc Natl Acad Sci USA* **102**: 9772–9777.
- Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP *et al.* (2006). Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. *Proc Natl Acad Sci USA* **103**: 13646–13651.
- Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR *et al.* (2006). Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. *Circ Res* **99**: 442–450.
- Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ (2007). Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. *Prostaglandins Other Lipid Mediat* **82**: 50–59.
- Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD (2005). Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. *Proc Natl Acad Sci USA* **102**: 2186–2191.
- Spector AA, Fang X, Snyder GD, Weintraub NL (2004). Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. *Prog Lipid Res* **43**: 55–90.
- Watanabe T, Schulz D, Morisseau C, Hammock BD (2006). High-throughput pharmacokinetic method: Cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis. *Anal Chim Acta* **559**: 37–44.
- Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ *et al.* (2006). Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. *Proc Natl Acad Sci USA* **103**: 18733–18738.
- Zhang WR, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C *et al.* (2007). Soluble epoxide hydrolase: a novel therapeutic target in stroke. *J Cerebral Blood Flow Metab* **27**: 1931–1940.
- Zhao XY, Incho EW, Morisseau C, Hammock BD, Imig JD (2002). Soluble epoxide hydrolase regulates renal microvascular angiotensin II reactivity in hypertension. *FASEB J* **16**: A418–A418.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1 Optimum tandem mass conditions and key fragmentation of the soluble epoxide hydrolase inhibitors

Table S2 Optimum tandem mass conditions of targeted oxylipin mediators

Table S3 The solvent gradient programme for chromatographic separation of oxylipin mediators

Table S4 Pharmacokinetic parameters of soluble epoxide hydrolase inhibitors after oral gavage and i.v. injection with non-compartmental analysis

Table S5 Plasma levels of individual oxylipins in a murine sepsis model

Table S6 Pharmacokinetic parameters of *t*-AUCB (after s.c. injection with non-compartmental analysis)

Table S7 The absorption rate constant of soluble epoxide hydrolase inhibitors following oral or s.c. administration

Appendix S1 The equations for pharmacokinetic parameters with compartmental analysis

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.